BioVie Inc Ordinary Shares - Class A

BioVie released results from the phase‑2 SUNRISE‑PD study in 57 untreated early‑stage Parkinson patients. Bezisterim showed significant improvements versus placebo in motor and non‑motor symptoms (MDS‑UPDRS, EPNIC‑15) and reduced biomarkers of neuroinflammation. In the subgroup with platelet counts >230 x10^3/µL, benefits were seen across all clinical measures. The safety profile was comparable to placebo; no serious adverse events were reported. » More on de.investing.com

BioVie presented results for the quarter ended Dec. 31, 2025, reporting a loss per share of $0.77; in the year-ago quarter the loss was $4.60 per share. The figures were presented at a financial conference on Feb. 6, 2026. » More on finanzen.net

Shareholders of BioVie approved at the annual meeting the amendment and restatement of the 2019 omnibus equity incentive plan, increasing the number of authorized common shares for awards to 3,100,000. The amended plan became effective on November 10, 2025, and is intended to allow equity-based compensation for employees, directors and consultants to attract and retain personnel and align interests with those of shareholders. BioVie, with a market capitalization of USD 11.3 million, shows a strong liquidity ratio (current ratio 15.83) but continues to struggle with profitability; all director nominees and key proposals were also approved at the meeting. The class A common shares and related warrants trade under the symbols BIVI and BIVIW. » More on de.investing.com